Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc., No. 15-1588 (Fed. Cir. Mar. 18, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Warner Chilcott Company, L LC and Warner Chilcott (US), L LC ( collectively, “Warner Chilcott”) appeal from the deci sion of the United States District Court for the District of Ne w Jersey holding claim 1 6 of U.S. Patent 7,645,459 (“the ’459 patent”) and claim 20 of U.S. Patent 7,645,460 (“the ’460 patent”) invalid as obviou s. Warner Chilcott Co., LLC v. Teva Pharm. USA, Inc. , 89 F. Supp. 3d 641 (D.N.J. 2015) (“ Opinion”). Because the district court did not err in concluding that the asserted claims are invalid, we affirm.